Abstract
Background: Epilepsy continues to be a significant global health problem and the search for new drugs for its treatment remains an urgent task. 5-HT2 and GABAA-receptors are among promising biotargets for the search for new anticonvulsants.
Methods: New potential 5-HT2 and GABAA ligands in the series of substituted cinnamoyl derivatives of 3,4,6,7,8,9-hexahydrodibenzo[b,d]furan-1-(2H)-one oxime were designed using pharmacophore model and molecular docking analysis. The synthesis of new compounds was carried out from 3,4,6,7,8,9-hexahydrodibenzo[b,d]furan-1(2H)-one oxime and substituted cinnamoyl chlorides. The anticonvulsant activity of new substances has been established using the maximal electroshock seizure test.
Results: Several synthesized substituted cinnamoyl derivatives of 3,4,6,7,8,9-hexahydrodibenzo [b,d]furan-1-(2H)-one oxime significantly reduced the severity of convulsive manifestations and completely prevented the death of animals after MES. The structure-activity relationship was investigated. The most effective compound was found to be GIZH-348 (1g) (3,4,6,7,8,9-hexahydrodibenzo[ b,d]furan-1(2Н)-one О-(4-chlorophenyl)acryloyl)oxime) at the doses of 10-20 mg/kg.
Conclusion: Molecular and pharmacophore modelling methods allowed us to create a new group of substituted cinnamoyl derivatives of 3,4,6,7,8,9-hexahydrodibenzo[b,d]furan-1-(2H)-one oxime with anticonvulsant activity.
Keywords: Anticonvulsant, MES test, dibenzofuranes, oximes, docking studies, cinnamoyl derivatives.
[http://dx.doi.org/10.1111/epi.13084] [PMID: 26216617]
[http://dx.doi.org/10.1111/epi.17165] [PMID: 35195894]
[http://dx.doi.org/10.1016/j.yebeh.2014.12.043] [PMID: 25843340]
[http://dx.doi.org/10.1016/j.yebeh.2005.01.002] [PMID: 15820346]
[http://dx.doi.org/10.1212/WNL.0b013e3181eccfb5] [PMID: 20697103]
[http://dx.doi.org/10.4102/phcfm.v12i1.2162] [PMID: 32634006]
[http://dx.doi.org/10.1007/s11094-018-1763-z]
[http://dx.doi.org/10.1007/s11094-019-01964-7]
[http://dx.doi.org/10.1007/s00044-019-02422-5]
[http://dx.doi.org/10.1007/s11094-019-01978-1]
[http://dx.doi.org/10.1007/s11094-019-02015-x]
[http://dx.doi.org/10.1007/s11094-020-02112-2]
[http://dx.doi.org/10.1007/s11094-021-02309-z]
[http://dx.doi.org/10.1111/j.1471-4159.2006.04277.x] [PMID: 17212700]
[http://dx.doi.org/10.1016/j.neuropharm.2016.04.016] [PMID: 27085605]
[http://dx.doi.org/10.1111/jnc.15769] [PMID: 36681890]
[http://dx.doi.org/10.2174/1381612823666170809100230] [PMID: 28799512]
[http://dx.doi.org/10.1016/j.ejmech.2012.08.037] [PMID: 23085104]
[http://dx.doi.org/10.1016/j.pharep.2018.06.007] [PMID: 30316046]
[http://dx.doi.org/10.1080/10286020.2012.724400] [PMID: 23088613]
[http://dx.doi.org/10.1016/j.jphs.2015.07.021] [PMID: 26260747]
[http://dx.doi.org/10.3390/molecules23010076] [PMID: 29286347]
[http://dx.doi.org/10.1002/cmdc.201500153] [PMID: 26083325]
[http://dx.doi.org/10.1016/S1474-4422(07)70215-6] [PMID: 17706563]
[http://dx.doi.org/10.1002/ddr.21538] [PMID: 30973979]
[http://dx.doi.org/10.3389/fphar.2015.00046] [PMID: 25852551]
[http://dx.doi.org/10.1002/epi4.12580] [PMID: 35075810]
[http://dx.doi.org/10.1016/j.neuron.2015.03.042] [PMID: 26050032]
[http://dx.doi.org/10.1002/ejoc.201600975]
[http://dx.doi.org/10.1021/ed067pA304]
[http://dx.doi.org/10.1016/j.tetasy.2016.07.003]
[http://dx.doi.org/10.1002/jhet.4455]
[http://dx.doi.org/10.1016/j.ejmech.2013.04.068] [PMID: 23747810]
[http://dx.doi.org/10.1021/ma034793w]
[PMID: 2401012]
[http://dx.doi.org/10.1039/P29950002257]
[http://dx.doi.org/10.1021/jo00378a012]
[http://dx.doi.org/10.1007/BF00824304]
[http://dx.doi.org/10.1002/bscb.19660750703]
[http://dx.doi.org/10.1021/jm0499615] [PMID: 15163208]
[http://dx.doi.org/10.1055/s-1978-24686]
[http://dx.doi.org/10.1016/j.tet.2005.04.001]
[http://dx.doi.org/10.1021/ol800829q] [PMID: 18507391]